Pulmonx Inc. (www.pulmonx.com) has announced new clinical data from its Chartis multi-center study 1, presented at the American Thoracic Society’s 2011 International Conference. This definitive data clearly demonstrates that by using the Chartis® Pulmonary Assessment System to plan Zephyr® valve treatments physicians can consistently treat a broad spectrum of emphysema patients.
